Radiotherapy (RT) for bronchopulmonary AIDS-related Kaposi's sarcoma (KS) (Meeting abstract). NLM AIDSLINE Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Radiotherapy (RT) for bronchopulmonary AIDS-related Kaposi's sarcoma (KS) (Meeting abstract).

Proc Annu Meet Am Soc Clin Oncol; 12:A9 1993. Unique Identifier : AIDSLINE ICDB/93694409
Routy JP; Methot F; Simard P; Beaulieu R; Toma E; Dumont M; Centre de recherche, Hotel-Dieu Hosp., Montreal, Quebec H2W 1T8,; Canada,

Abstract: The aim of this prospective study was to evaluate the efficacy and tolerance of thoracic RT for bronchopulmonary KS, in patients (pts) who never received chemotherapy. Between September 1990 and September 1992, 17 male pts with lung biopsy-proven KS, and/or positive bronchoscopy findings were included. Ten had experienced an opportunistic infection within a mean of 18 mo prior to entry. The mean CD4+ count: 41/mm3 (14-116). The condition of 4 pts worsened rapidly and they were unable to receive RT. The treatment schedule was 10 Gy in 10 fractions over 2 wk (anterior and posterior fields). For cutaneous KS, 11 pts had received RT, and 4 pts interferon prior to treatment. Antipneumocystis prophylaxis was used in all pts. Improvement of dyspnea was noted in 7/13 cases 1 mo after the start of treatment. Radiologic improvement was obvious in 2 cases. The cause of death of 10 pts was respiratory failure related to KS and the median survival time (actuarial method) was 5.6 mo. We conclude that RT is well tolerated. It is useful as a palliative treatment to relieve dyspnea, but the duration of improvement is short, and the objective response is rare.
Keywords: Acquired Immunodeficiency Syndrome/MORTALITY/*RADIOTHERAPY Cause of Death Follow-Up Studies Human Lung Neoplasms/MORTALITY/*RADIOTHERAPY Prospective Studies Radiotherapy Dosage Sarcoma, Kaposi's/MORTALITY/*RADIOTHERAPY Skin Neoplasms/MORTALITY/*RADIOTHERAPY Survival Rate ABSTRACTKWDacquiredimmunodeficiencysyndrome/mortality/KWDradiotherapycauseofdeathfollow-upstudieshumanlungneoplasms/mortality/KWDradiotherapyprospectivestudiesradiotherapydosagesarcoma,kaposi's/mortality/KWDradiotherapyskinneoplasms/mortality/KWDradiotherapysurvivalrateabstract
931230
M93C0818

Copyright © 1993 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .